Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
Baxter
Express Scripts
Moodys
McKinsey

Last Updated: November 19, 2019

DrugPatentWatch Database Preview

Cetuximab - Biologic Drug Details

See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for cetuximab

Identify potential brand extensions & biosimilar entrants

SponsorPhase
TakedaEarly Phase 1
Presage BiosciencesEarly Phase 1
Second Affiliated Hospital, School of Medicine, Zhejiang UniversityN/A

See all cetuximab clinical trials

Recent Litigation for cetuximab

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
CELGENE CORPORATION v. DR. REDDY'S LABORATORIES, LTD.2019-07-12
2654 Highway 169, LLC2016-04-13
Andrulis Pharmaceuticals Corp. v. Celgene Corp.2013-10-02

See all cetuximab litigation

PTAB Litigation
PetitionerDate
Forty Seven, Inc.2018-01-08
Forty Seven, Inc.2016-08-08
Forty Seven, Inc.2016-08-05

See all cetuximab litigation

Pharmacology for cetuximab
Mechanism of ActionHER1 Antagonists

Company Disclosures: US Patents for cetuximab

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Start Trial Rhone-Poulenc Rorer International (Holdings), Inc. (Greenville, DE) 2018-04-17 RX Orphan company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for cetuximab

These patents were identified by searching patent claims

Supplementary Protection Certificates for cetuximab

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
140 Estonia   Start Trial
780 Luxembourg   Start Trial PRODUCT NAME: TRASTUZUMAB ET HYALURONIDASE HUMAINE RECOMBINANTE; FIRST REGISTRATION DATE: 20130826
116 Luxembourg   Start Trial 91116, EXPIRES: 20140915
0822 Netherlands   Start Trial PRODUCT NAME: RITUXIMAB EN RECOMBINANT HUMAAN HYALURONIDASE; REGISTRATION NO/DATE: EU/1/98/067/003 - UITVOERINGSBESLUIT C(2014)2048 20140326
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Boehringer Ingelheim
Harvard Business School
Express Scripts
Colorcon
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.